연구동향 분석
박사

관상동맥중재술을 시행하는 동시대의 협심증 또는 심근경색 환자에서 베타 차단제가 예후에 미치는 효과 : 국가통계를 이용한 분석 = Prognostic effect of beta-adrenergic receptor blockades in patients with coronary artery disease undergoing contemporary percutaneous coronary intervention: A nationwide cohort study

이필형 2020년

논문상세정보
인용/피인용
' 관상동맥중재술을 시행하는 동시대의 협심증 또는 심근경색 환자에서 베타 차단제가 예후에 미치는 효과 : 국가통계를 이용한 분석 = Prognostic effect of beta-adrenergic receptor blockades in patients with coronary artery disease undergoing contemporary percutaneous coronary intervention: A nationwide cohort study' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • angina pectoris
  • beta-blocker
  • coronary artery disease
  • myocardial infarction
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
283 0

0.0%

' 관상동맥중재술을 시행하는 동시대의 협심증 또는 심근경색 환자에서 베타 차단제가 예후에 미치는 효과 : 국가통계를 이용한 분석 = Prognostic effect of beta-adrenergic receptor blockades in patients with coronary artery disease undergoing contemporary percutaneous coronary intervention: A nationwide cohort study' 의 참고문헌

  • beta-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction
    69:2710-2720 [2017]
  • Zeymer U and Acute Coronary Syndromes Registry i. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction : predictors and outcomes of nonadherence
    17:576-81 [2010]
  • Trends in myocardial infarction secondary prevention : The National Health and Nutrition Examination Surveys ( NHANES ) , 1999-2012
    4 [2015]
  • Thuresson M and Oie E. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction
    0.746527778 [2016]
  • Thuresson M and Janzon M. Cardiovascular risk in post-myocardial infarction patients : nationwide real world data demonstrate the importance of a long-term perspective
    36:1163-70 [2015]
  • The effect of carvedilol on morbidity and mortality in patients with chronic heart failure . U.S. Carvedilol Heart Failure Study Group
    334:1349-55 [1996]
  • Sharpe N and MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure . A systematic overview of randomizedControlled trials
    18:560-5 [1997]
  • SJ . Model for assessingCardiovascular risk in a
    2014
  • S , Bax J , Boersma E , Bueno H ,Caso P , Dudek D , Gielen S , Huber K , Ohman M , Petrie MC , Sonntag F , Uva MS , Storey RF , Wijns W , Zahger D and Guidelines ESCCfP . ESC Guidelines for the management
    without
  • Prevalence ofCardiovascular medication on secondary prevention after myocardial infarction inChina between 1995-2015 : A systematic review and meta-analysis
    12 : e0175947 . [2017]
  • Mukherjee D and Lichstein E. Benefits of beta blockers in patients with heart failure and reduced ejection fraction : network meta-analysis
    346 : f55 . [2013]
  • L. A meta-analysis of the effects of beta-adrenergic blockers in chronic heart failure
    12:2489-2496 [2016]
  • J. beta Blockade after myocardial infarction : systematic review and meta regression analysis .
    318:1730- 7 . [1999]
  • Increasing prescription of drugs for secondary prevention after myocardial infarction
    311:917-8 [1995]
  • Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial
    357:1385-90 [2001]
  • Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction : randomised placebo-controlled trial
    366:1622-32 [2005]
  • DP and Yusuf S. The Evolution of beta-Blockers in Coronary Artery Disease and Heart Failure ( Part 1/5 )
    74:672-682 [2019]
  • Clinical outcomes with betablockers for myocardial infarction : a meta-analysis of randomized trials
    127:939-53 [2014]
  • Chen M and Huang DJ . Meta-Analysis of Relation Between Oral beta-Blocker Therapy and Outcomes in Patients With Acute Myocardial
    Am
  • Beta blockers prevent cardiac death following a myocardial infarction : so why are so many infarct survivors discharged without beta blockers ?
    78:821-2 [1996]
  • Adrenergic nervous system in heart failure : pathophysiology and therapy
    113:739-53 [2013]
  • 8. Task Force on the management of STseamiotESoC, Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez- Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P and Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.
  • 28. Evaluation of decreased usage of betablockers after myocardial infarction in the SWEDEHEART Registy (REDUCE-SWEDEHEART). Available at: http://clinicaltrials.gov/ct2/show/NCT03278509. Accessed October 31, 2019.
  • 27. Lee PH, Park GM, Kim YH, Yun SC, Chang M, Roh JH, Yoon SH, Ahn JM, Park DW, Kang SJ, Lee SW, Lee CW, Park SW and Park SJ. Effect of Beta Blockers and Renin- Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Medicine (Baltimore). 2016;95:e2971.
  • 2. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-69.
  • 15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
  • 14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
  • , Gibbons RJ , Grundy SM , Hiratzka LF , Jones DW , Lloyd-Jones DM , Minissian M , Mosca L , Peterson ED , Sacco RL , Spertus J , Stein JH , Taubert KA , World Heart F and the
    Secondary